Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system
Compositions and methods for targeted treatment of cancer are disclosed. In particular, the invention relates to methods of targeting anti-cancer therapy to cells exhibiting aberrant signaling associated with cancer pathogenesis by administering synthetic signaling proteins that couple detection of an oncogenic signal to release of therapeutic agents into cancerous cells.
1. A vector system comprising one or more viral vectors comprising:
a) a first expression cassette encoding a first fusion protein comprising a protease connected to a phosphotyrosine binding (PTB) domain capable of binding to a first constitutively phosphorylated tyrosine residue on an endogenous hyperactive receptor tyrosine kinase; and
b) a second expression cassette encoding a second fusion protein comprising a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:21, and SEQ ID NO:22, or a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:21, and SEQ ID NO:22.
2. The vector system of claim 1 , wherein the one or more viral vectors comprise a bicistronic vector comprising the first expression cassette and the second expression cassette.
3. The vector system of claim 2 , wherein the bicistronic vector comprises a viral T2A peptide or an internal ribosome entry site (IRES).
4. The vector system of claim 1 , wherein said one or more viral vectors are selected from the group consisting of a lentivirus vector and an adeno-associated virus vector.
5. The vector system of claim 1 , wherein the one or more viral vectors are non-integrating viral vectors.
6. The vector system of claim 1 , wherein the protease is the hepatitis C virus (HCV) NS3 protease.
7. The vector system of claim 1 , wherein the first fusion protein further comprises a degron, wherein degradation activity of the degron is inhibited by the binding of the PTB domain of the first fusion protein to the first constitutively phosphorylated tyrosine residue on the endogenous hyperactive receptor tyrosine kinase such that the first fusion protein accumulates preferentially in cancerous cells.
8. The vector system of claim 7 , wherein the degron is located in a loop of the PTB domain.
9. The vector system of claim 7 , wherein the degron is a HIF1a degron.
10. The vector system of claim 9 , wherein the first fusion protein comprises the amino acid sequence of SEQ ID NO:17, or a sequence having at least 90% identity to the sequence of SEQ ID NO:17.
11. The vector system of claim 1 , wherein the PTB is Shc PTB.
12. A vector system comprising a viral vector comprising a sequence selected from the group consisting of SEQ ID NO:23 and SEQ ID NO:24, or a sequence having at least 90% identity to the sequence selected from the group consisting of SEQ ID NO:23 and SEQ ID NO:24.
13. The vector system of claim 1 , further comprising a third expression cassette encoding a viral capsid protein capable of assembly into a viral-like particle.
14. A composition comprising the vector system of claim 1 and a pharmaceutically acceptable excipient.
15. A virus-like particle comprising the vector system of claim 1 and a viral capsid protein.
16. The virus-like particle of claim 15 , further comprising a viral envelope protein.
17. A composition comprising the virus-like particle of claim 15 .
18. The composition of claim 17 , further comprising a pharmaceutically acceptable excipient.
19. A method for producing viral-like particles (VLPs), the method comprising:
a) transforming a host cell with the vector system of claim 13 ; and
b) culturing the transformed host cell under conditions whereby capsid proteins are expressed and assembled into VLPs encapsulating the vector system.
20. A method for targeted treatment of a cancer associated with hyperactivity of a receptor tyrosine kinase, the method comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 14 .
21. The method of claim 20 , wherein the hyperactive receptor tyrosine kinase is a hyperactive ErbB receptor tyrosine kinase.
22. The method of claim 20 , wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, lung cancer, glioma, colorectal cancer, head and neck cancer, and brain cancer.
23. A method for targeted treatment of a cancer associated with hyperactivity of a receptor tyrosine kinase, the method comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 18 .
24. The method of claim 23 , wherein the hyperactive receptor tyrosine kinase is a hyperactive ErbB receptor tyrosine kinase.
25. The method of claim 23 , wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, lung cancer, glioma, colorectal cancer, head and neck cancer, and brain cancer.
26. A kit comprising the vector system of claim 1 and instructions for treating cancer.
27. A composition comprising the vector system of claim 12 and a pharmaceutically acceptable excipient.
28. A virus-like particle comprising the vector system of claim 12 and a viral capsid protein.
29. The virus-like particle of claim 28 , further comprising a viral envelope protein.
30. A composition comprising the virus-like particle of claim 28 .
31. The composition of claim 30 , further comprising a pharmaceutically acceptable excipient.
32. A method for producing viral-like particles (VLPs), the method comprising:
a) transforming a host cell with the vector system of claim 12 ; and
b) culturing the transformed host cell under conditions whereby capsid proteins are expressed and assembled into VLPs encapsulating the vector system.
33. A method for targeted treatment of a cancer associated with hyperactivity of a receptor tyrosine kinase, the method comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 27 .
34. The method of claim 33 , wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, lung cancer, glioma, colorectal cancer, head and neck cancer, and brain cancer.
35. A method for targeted treatment of a cancer associated with hyperactivity of a receptor tyrosine kinase, the method comprising administering to a subject in need thereof a therapeutically effective amount of the composition of claim 31 .
36. The method of claim 35 , wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, lung cancer, glioma, colorectal cancer, head and neck cancer, and brain cancer.